Background
==========

T-VEC is an oncolytic immunotherapy derived from herpes simplex virus type-1 designed to selectively replicate within tumors and to produce GM-CSF to enhance systemic antitumor immune responses. OPTiM, a randomized Phase III trial of T-VEC vs GM-CSF in patients with unresected melanoma with regional or distant metastases met the primary objective of an improvement in durable response rate (response lasting continuously for ≥6 months) with T-VEC versus GM-CSF (16% vs 2%, respectively; *P*\<0.001). Most common adverse events with T-VEC were fatigue, chills, and pyrexia. No ≥grade 3 adverse events occurred in ≥3% of patients in either arm (Andtbacka et al., *J Clin Oncol*2013,32\[suppl\]:LBA9008). At the primary analysis (PA) of secondary OS endpoint, with median follow-up of 44 (range, 32-59) months and 189 events in the T-VEC arm and 101 events in the GM-CSF arm, median (95%CI) OS was 23.3 (19.5-29.6) months for T-VEC and 18.9 (16.0-23.7) months for GM-CSF (hazard ratio \[HR\]=0.79; 95%CI = 0.62-1.00; *P*= 0.051) (Kaufman et al., *J Clin Oncol*2014,32\[suppl\]:9008a). A planned analysis of OS at 3 years from the last randomization is presented here.

Methods
=======

Eligible patients were ≥18 years old; had ECOG performance status (PS) ≤1; unresectable melanoma stage IIIB/C/IV; injectable cutaneous, subcutaneous (SC) or nodal lesions; LDH≤1.5X upper limit of normal; ≤3 visceral lesions (excluding lung), none\>3 cm. Patients were randomized 2:1 to intralesional T-VEC (initially ≤4 mL x10^6^pfu/mL, then after 3 wks, ≤4 mL x10^8^pfu/mL q2w) or SC GM-CSF (125 µg/m^2^qd × 14 ds q4w).

Results
=======

Of 436 patients in the intent-to-treat analysis, 295 (68%) patients received T-VEC and 141 (32%) patients received GM-CSF; 57% were men; median age 63 yrs. At time of the final OS analysis with median follow-up of 49 months \[range, 37-63\], only 1 additional event occurred (T-VEC arm). Median (95%CI) OS was 23.3 months (95%CI = 19.5-29.6) for T-VEC and 18.9 months (16.0-23.8) for GM-CSF; HR = 0.80 (95%CI = 0.62-1.01), *P*= 0.06 (descriptive). Five-year survival for the T-VEC arm was 33.4% (95%CI = 27.7-39.2). T-VEC effect on OS was most pronounced in patients with stage IIIB/C/IVM1a melanoma (HR = 0.57; 95%CI = 0.41-0.81, *P*= 0.001 \[descriptive\]) and in patients with treatment-naive disease (HR = 0.52; 95%CI = 0.36-0.75, *P*\< 0.001 \[descriptive\]).

Conclusions
===========

With \>4 years of median follow-up for survival, a persistent relevant OS effect was demonstrated with further follow-up. Long-term follow-up continues in the registry trial (NCT02173171). T-VEC represents a novel potential therapy for patients with regionally and distantly metastatic melanoma.
